Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ranibizumab + triamcinolone
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravitreal, Ophthalmic
01
Overview
Ranibizumab + triamcinolone is a combination therapy used in ophthalmology for the treatment of retinal diseases such as neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Ranibizumab is a monoclonal antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and leakage. Triamcinolone acetonide is a corticosteroid with anti-inflammatory properties, which helps reduce inflammation and edema in the retina. The combination aims to provide both anti-VEGF and anti-inflammatory effects, potentially improving outcomes and reducing the need for frequent injections[1][3][5].
- Other names
- ranibizumab and triamcinoloneranibizumab plus triamcinolone
02
Targets
GR (Glucocorticoid receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on ranibizumab + triamcinolone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ranibizumab + triamcinolone.